- Home
- CATX vs AGMB Comparison
CATX vs AGMB Comparison
Compare CATX & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | AGMB |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | 62 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.9M | 562.4M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CATX | AGMB |
|---|---|---|
| Price | $3.43 | $12.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | $12.11 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 2.1M | 109.4K |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.96 | $8.75 |
| 52 Week High | $6.16 | $17.82 |
Technical Indicators
Market Signals| Indicator | CATX | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 54.75 |
| Support Level | $2.85 | $9.54 |
| Resistance Level | $4.27 | $14.63 |
| Average True Range (ATR) | 0.19 | 1.63 |
| MACD | 0.08 | 0.51 |
| Stochastic Oscillator | 66.06 | 44.02 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.